Technical note from the Institutional Program for Drug Policy, Human Rights and Mental Health of the Oswaldo Cruz Foundation (Fiocruz), released this Wednesday (19), indicates that a growing number of studies point to the therapeutic potential of cannabinoids, including cannabidiol (CBD) and delta-9-tetrahydrocannabinol (THC), for different clinical conditions and illnesses.
According to the note, these studies present different levels of evidence, that is, for each condition there is, at the present time, greater or lesser scientific robustness that proves the safety and efficacy of the therapeutic application.
Subscribe to O POVO+
Get access to all exclusive content, columnists, unlimited access and discounts in stores, pharmacies and much more.
Related news:
The researchers responsible for the document point out that some research is conclusive in pointing out the safety and efficacy of cannabinoids in reducing symptoms and improving the health status of chronic pain, spasticity (a motor disorder characterized by increased muscle tone), neuropsychiatric disorders and nausea, vomiting and loss of appetite linked to chemotherapy treatment.
In addition to detailing evidence and technical references on health conditions, the technical note also reinforces the need to advance in the development of research in Brazil, with clinical studies of different conditions, training doctors and other health professionals on the therapeutic use of cannabis and derivatives. “This will allow them to be able to prescribe and treat with more confidence and knowledge and also in the regulation of cannabis-based products, so that they are produced nationally and distributed in a safe and effective way”, says Fiocruz.
For the researchers, “it is essential to ensure comprehensive and efficient regulation, which enables the production, prescription and free and universal access, by the Unified Health System (SUS), to a wide range of pharmaceutical forms of cannabis and derivatives, always supported by by solid evidence of safety and therapeutic efficacy”.
The objective of the document is to offer technical support to institutions responsible for legislation, regulation, research, production, standardization, distribution and use of cannabis and derivatives for therapeutic purposes in Brazil and for society in general.
Doubts, Reviews and Suggestions? Talk to us
Tags
